BRPI0922736A2 - sal de citrato de 11-(pirrolidin-1-il-etóxi)-14-dioxina-5-7,26-triaza-tetraciclo [19.3.1.1(2.6).1(8.12)] ehptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno - Google Patents

sal de citrato de 11-(pirrolidin-1-il-etóxi)-14-dioxina-5-7,26-triaza-tetraciclo [19.3.1.1(2.6).1(8.12)] ehptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Info

Publication number: BRPI0922736A2
Authority: BR; Brazil
Prior art keywords: ehptacosa; tetracyclo; triaza; dioxin; decene
Prior art date: 2008-12-11

Application number

BRPI0922736A

Other languages

English (en)

Inventor

Deodaunia William Anthony

Dymock Bryan

Hsia Angeline Lee Cheng

Original Assignee

Sstarbio Pte Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-11

Filing date

2009-12-09

Publication date

2017-10-31

2009-12-09 Application filed by Sstarbio Pte Ltd filed Critical Sstarbio Pte Ltd

2017-10-31 Publication of BRPI0922736A2 publication Critical patent/BRPI0922736A2/pt

2021-11-09 Publication of BRPI0922736A8 publication Critical patent/BRPI0922736A8/pt

2022-02-22 Publication of BRPI0922736B1 publication Critical patent/BRPI0922736B1/pt

Links

150000001860 citric acid derivatives Chemical class 0.000 title 1
-1 pyrrolidin-1-yl-ethoxy Chemical group 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/22—Tricarboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
- C07D201/02—Preparation of lactams
- C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)

BRPI0922736-9A 2008-12-11 2009-12-09 Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste BRPI0922736B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12166808P	2008-12-11	2008-12-11
US61/121.668		2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en)	2008-12-11	2009-12-09	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (3)

Publication Number	Publication Date
BRPI0922736A2 true BRPI0922736A2 (pt)	2017-10-31
BRPI0922736A8 BRPI0922736A8 (pt)	2021-11-09
BRPI0922736B1 BRPI0922736B1 (pt)	2022-02-22

Family

ID=41666397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0922736-9A BRPI0922736B1 (pt)	2008-12-11	2009-12-09	Sal de citrato de 11-(2-pirrolidin-1-il-etóxi)-14,19-dioxa5,7,26-triaza-tetraciclo [19.3.1.1(2,6).1 (8,12)]heptacosa1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno, composição farmacêutica compreendendo este e uso deste

Country Status (23)

Country	Link
US (2)	US8980873B2 (pt)
EP (1)	EP2376499B1 (pt)
JP (1)	JP5669748B2 (pt)
KR (1)	KR101729918B1 (pt)
CN (1)	CN102282148B (pt)
AR (2)	AR074724A1 (pt)
AU (1)	AU2009325147B2 (pt)
BR (1)	BRPI0922736B1 (pt)
CA (1)	CA2746058C (pt)
DK (1)	DK2376499T3 (pt)
ES (1)	ES2536558T3 (pt)
HR (1)	HRP20150428T1 (pt)
IL (3)	IL213418A0 (pt)
MX (1)	MX2011006206A (pt)
MY (1)	MY160005A (pt)
NZ (1)	NZ593223A (pt)
PL (1)	PL2376499T3 (pt)
PT (1)	PT2376499E (pt)
RU (1)	RU2527970C2 (pt)
SG (1)	SG171907A1 (pt)
TW (1)	TWI449705B (pt)
WO (1)	WO2010068181A1 (pt)
ZA (1)	ZA201104032B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2376500T3 (pl) *	2008-12-11	2015-07-31	Cti Biopharma Corp	Sól maleinianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26 triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
CN102282148B (zh)	2008-12-11	2014-12-24	Cti生物医药有限公司	11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐
US9090623B2 (en)	2012-04-13	2015-07-28	Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd.	Compound JK12A and preparation thereof
CN105061467B (zh) *	2015-08-28	2017-08-25	苏州立新制药有限公司	一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5728536A (en)	1993-07-29	1998-03-17	St. Jude Children's Research Hospital	Jak kinases and regulation of Cytokine signal transduction
US6136595A (en)	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
CA2446988A1 (en) *	2001-05-14	2002-11-21	Pfizer Products Inc.	The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
US6433018B1 (en)	2001-08-31	2002-08-13	The Research Foundation Of State University Of New York	Method for reducing hypertrophy and ischemia
IL161326A0 (en) *	2001-11-29	2004-09-27	Pfizer Prod Inc	Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN101360751B (zh)	2005-11-16	2011-09-14	S*Bio私人有限公司	氧连接的嘧啶衍生物
CN102282148B (zh)	2008-12-11	2014-12-24	Cti生物医药有限公司	11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐

2009
- 2009-12-09 CN CN200980150325.5A patent/CN102282148B/zh active Active
- 2009-12-09 KR KR1020117015738A patent/KR101729918B1/ko active Active
- 2009-12-09 AU AU2009325147A patent/AU2009325147B2/en active Active
- 2009-12-09 DK DK09788621T patent/DK2376499T3/en active
- 2009-12-09 PT PT97886212T patent/PT2376499E/pt unknown
- 2009-12-09 US US13/133,297 patent/US8980873B2/en active Active
- 2009-12-09 MX MX2011006206A patent/MX2011006206A/es active IP Right Grant
- 2009-12-09 JP JP2011540664A patent/JP5669748B2/ja active Active
- 2009-12-09 ES ES09788621.2T patent/ES2536558T3/es active Active
- 2009-12-09 NZ NZ593223A patent/NZ593223A/xx unknown
- 2009-12-09 BR BRPI0922736-9A patent/BRPI0922736B1/pt active IP Right Grant
- 2009-12-09 PL PL09788621T patent/PL2376499T3/pl unknown
- 2009-12-09 MY MYPI2011002647A patent/MY160005A/en unknown
- 2009-12-09 CA CA2746058A patent/CA2746058C/en active Active
- 2009-12-09 EP EP09788621.2A patent/EP2376499B1/en active Active
- 2009-12-09 SG SG2011040060A patent/SG171907A1/en unknown
- 2009-12-09 RU RU2011126173/04A patent/RU2527970C2/ru active
- 2009-12-09 WO PCT/SG2009/000473 patent/WO2010068181A1/en not_active Ceased
- 2009-12-09 HR HRP20150428TT patent/HRP20150428T1/hr unknown
- 2009-12-11 AR ARP090104834A patent/AR074724A1/es not_active Application Discontinuation
- 2009-12-11 TW TW098142605A patent/TWI449705B/zh active
2011
- 2011-05-31 ZA ZA2011/04032A patent/ZA201104032B/en unknown
- 2011-06-06 IL IL213418A patent/IL213418A0/en unknown
2015
- 2015-02-13 US US14/621,726 patent/US9624242B2/en active Active
2017
- 2017-01-26 IL IL250310A patent/IL250310A0/en unknown
2019
- 2019-03-20 AR ARP190100701A patent/AR114133A2/es unknown
2021
- 2021-12-26 IL IL289379A patent/IL289379A/en unknown

Also Published As

Publication number	Publication date
RU2011126173A (ru)	2013-01-20
WO2010068181A1 (en)	2010-06-17
JP5669748B2 (ja)	2015-02-12
MY160005A (en)	2017-02-15
US8980873B2 (en)	2015-03-17
HRP20150428T1 (xx)	2015-06-19
CN102282148B (zh)	2014-12-24
DK2376499T3 (en)	2015-05-04
US20150322084A1 (en)	2015-11-12
IL289379A (en)	2022-02-01
RU2527970C2 (ru)	2014-09-10
IL250310A0 (en)	2017-03-30
EP2376499B1 (en)	2015-02-25
AU2009325147B2 (en)	2014-08-14
NZ593223A (en)	2013-08-30
PT2376499E (pt)	2015-06-03
JP2012511571A (ja)	2012-05-24
TWI449705B (zh)	2014-08-21
PL2376499T3 (pl)	2015-07-31
CA2746058C (en)	2016-05-17
TW201028426A (en)	2010-08-01
ES2536558T3 (es)	2015-05-26
AR114133A2 (es)	2020-07-22
KR20110106344A (ko)	2011-09-28
CN102282148A (zh)	2011-12-14
MX2011006206A (es)	2011-07-20
SG171907A1 (en)	2011-07-28
WO2010068181A8 (en)	2011-08-18
AR074724A1 (es)	2011-02-09
HK1161877A1 (en)	2012-08-10
KR101729918B1 (ko)	2017-04-25
IL213418A0 (en)	2011-07-31
CA2746058A1 (en)	2010-06-17
US20110294831A1 (en)	2011-12-01
US9624242B2 (en)	2017-04-18
BRPI0922736A8 (pt)	2021-11-09
BRPI0922736B1 (pt)	2022-02-22
ZA201104032B (en)	2012-08-29
EP2376499A1 (en)	2011-10-19
AU2009325147A1 (en)	2011-06-23

Legal Events

Date	Code	Title	Description
2017-12-12	B25A	Requested transfer of rights approved	Owner name: CELL THERAPEUTICS, INC. (US)
2018-01-02	B25D	Requested change of name of applicant approved	Owner name: CTI BIOPHARMA CORP. (US)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-11-21	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-10-15	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2021-09-21	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-09-28	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-01-11	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-02-22	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

Publication	Publication Date	Title
CY2018024I1 (el)	2019-11-27	Παραγωγα διοξα-δικυκλο[3.2.1]οκταν-2,3,4-τριολης
NO2017026I1 (no)	2017-06-12	Alectinib (9-etyl-6,6-dimetyl-8-(4-morfolin-4-yl-piperidin-1-yl)-11-okso-6,11-dihydro-5H-benzo[b]-karbasol-3-karbonitril) eller salt eller solvat derav. (krav 1 i patentet)
BRPI1006113A2 (pt)	2016-02-16	"derivado de piridina".
BRPI0923047A2 (pt)	2015-12-08	"conjugados de proteínas-oligossacarídeos".
BRPI1011414A2 (pt)	2016-03-15	"método."
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
IL206765A0 (en)	2010-12-30	4,5-dihydro-oxazol-2-yl-amine derivatives
ITSA20100009U1 (it)	2010-09-11	Apparato per l'alimentazione.
BRPI0923732A2 (pt)	2016-01-19	"regeneração de catalisador".
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI1014388A2 (pt)	2016-04-05	preparação de sólido.
IL289379A (en)	2022-02-01	Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
BRPI0916395A2 (pt)	2016-02-16	compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
IT1397968B1 (it)	2013-02-04	Composizione pesticida acquosa.
BR112012000750A2 (pt)	2016-08-09	"sal citrato de 9e-15-(2-pirrolidin-1-il-etóxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14.18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno"
HRP20150413T8 (xx)	2015-08-14	11-(2-pirolidin-1-il-etoksi)-14,19-dioksa-5,7,26-triaza-tetraciklo[19.31.1(2,6).1(8,12)]heptakoza-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaen maleatna sol
EP2264029A4 (en)	2011-08-24	1,3-dihydroisobenzofuran DERIVATIVE
BRPI0907749A2 (pt)	2015-07-21	Derivados de 3,8-diaminotetrahidroquinolina
BRPI1011720A2 (pt)	2016-03-22	compostos de 1,1,1- tri-flúor-2 hidróxi-propila.
NL2003137A1 (nl)	2010-01-11	Landbouwmachine.
CL2008000598A1 (es)	2008-09-05	Procedimiento de preparacion de 3-metil-4-fenilisoxazolo [3,4-d]piridazin-7(6h)-ona.
BRPI0918503A2 (pt)	2015-09-22	processo de preparação da 1,6:2,3-dianidro-beta-d-manopiranose
BRPI0818848A2 (pt)	2015-04-14	Compostos de 2,3-di-idro-benzofurano
DE602007008319D1 (de)	2010-09-23	I.S.-Gerät